Femina Flora Oral





A combination of 16 bacterial strains particularly specified for the vaginal zone. The product contains 55 billion living microorganisms per capsule.

The GPS™ natural water-based enteric-coated vegetable capsule protects contents from stomach acids. The capsule only dissolves in the intestinal pH, which allows that the capsule content is delivered with 100% potency.

The GPS™ natural water-based enteric-coated vegetable capsule protects contents from stomach acids. The capsule only dissolves in the intestinal pH, which allows that the capsule content is delivered with 100% potency.



FORMAT: 30 enteric coated vegetables capsules

FORMULA

Ingredients: Potato starch, bacterial culture (55 billion live active healthy cells per capsule; see nutritional information), inulin (from chicory root, *Cichorium intybus*), arabinogalactan (from *Larix laricina*), antioxidant (sodium L-ascorbate), anticaking agent (magnesium salts of fatty acids), GPSTM enteric-coated vegetable capsule (glazing agent: hydroxypropylmethylcellulose; aqueous enteric-coating solution; purified water).

Nutritional information:	1 capsule
Human strains:	
Lactobacillus rhamnosus UB5115	19,000 billion CFU
Lactobacillus acidophilus UB5997	5.250 billion CFU
Lactobacillus casei UB1499	12.000 billion CFU
Bifidobacterium bifidum UB4280	2.000 billion CFU
Bifidobacterium breve UB8674	2.000 billion CFU
Bifidobacterium longum UB7691	2.000 billion CFU
Lactobacillus crispatus UB4719	0,750 billion CFU
Lactobacillus gasseri UB8141	0,750 billion CFU
Lactobacillus rhamnosus GG	0,300 billion CFU
Lactobacillus acidophilus LA-14	0,300 billion CFU
Plant strain:	
Lactobacillus plantarum UB2783	8.000 billion CFU
Dairy strains:	
Lactobacillus casei LC-11	0,300 billion CFU
Lactobacillus helveticus UB7229	0,500 billion CFU
Lactobacillus paracasei UB1978	0,600 billion CFU
Lactobacillus johnsonii UB3394	0,750 billion CFU
Lactobacillus reuteri UB2419	0,500 billion CFU
Inulin	10 mg
Arabinogalactan (AOS)	10 mg
CFU: Colony-Forming Unit Cells	

Cautions:

Consult with a professional before using this product if you have nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain; or if you have a special medical condition; or if you have an immunecompromised condition (e.g. lymphoma or AIDS). Discontinue use if symptoms of digestive upset persist beyond 3 days.

Recommended daily dose:

1-2 capsules daily.

If you are taking antibiotics, take this product at least 2-3 hours before or after taking them. Do not exceed the stated recommended daily dose.

Femina Flora Oral





Indications and uses:

- It helps maintain balanced vaginal flora.
- Vaginal infections caused by yeast (candidiasis) or bacteria (vaginosis).
- Prevention of recurring vaginal infections from both yeast and bacteria (ideal for prolonged use).

DETAILS:

FeminaFlora Oral is characterized by its selection of scientifically proven probiotic strains and complementary natural prebiotics. It's the ideal product for maintaining balanced vaginal flora and fighting vaginal infections.

Each capsule of **Femina**Flora Oral offers over 55 billion live cells, with 16 beneficial strains (10 of human origin, 5 dairy and 1 plant-derived). It contains over 31 billion CFUs of *Lactobacillus rhamnosus* and *Lactobacillus casei*. These 2 human strains are predominant in the vaginal flora and generate lactic acid, acidifying the vaginal pH and preventing the proliferation of pathogenic bacteria and yeasts. This formula also includes *Lactobacillus crispatus* and *Lactobacillus gasseri*, two of the most common probiotics in the vaginal flora, in addition to *Bifidobacterium breve* and *Lactobacillus johnsonii*. Our formula also includes two Bifidobacterium species that typically reside in the colon and that reinforce the immune system.

INGREDIENTS:

A healthy intestinal balance of *Lactobacillus* and *Bifidobacterium* is essential for replacing harmful microorganisms and creating an intestinal environment that suppresses excessive growth of opportunist microorganisms. The vagina shares many species of *Lactobacillus* with the intestine; these beneficial strains generate lactic acid which inhibits both infection by *Candida* and *bacterial vaginosis*.

Diverse clinical trials have shown that orally administered *Lactobacillus* (*rhamnosus*, *gasseri*, *crispatus*, *reuteri*, *plantarum*, *acidophilus*) populates the vaginal mucosa within one week (1-7). The administration of Lactobacillus rhamnosus and L reuteri together with antibiotic therapy (metronidazole) improves outcomes in bacterial vaginosis (8-9). *Lactobacillus gasseri* and *Lactobacillus johnsonii* generate lactic acid and hydrogen peroxide, which are able to eliminate pathogens associated with vaginosis (10-12). Lactobacillus crispatus is able to inhibit growth of Candida albicans that causes vaginal candidiasis (13-14).

FeminaFlora Oral contains additional Lactobacillus species that reinforce the broad spectrum of benefits of the diverse formula.

Our formula also contains over 4 billion CFUs of *Bifidobacterium bifidum* and *Bifidobacterium longum* (15-20); these probiotic species typically reside in the colon where they strengthen immune system performance.

<u>INULIN:</u> A fructooligosaccharide (FOS) from plants, extracted from the chicory root (*Cichorium intybus*). It acts as a prebiotic, creating an appropriate environment for probiotics, or beneficial microorganisms, to reproduce faster and in larger quantities $^{(21-23)}$. It increases the population of *Bifidobacterium* probiotics in the colon and reduces toxic metabolites and harmful enzymes. It prevents pathological and autogenous diarrhoea as well as constipation and protects liver function $^{(24)}$.

<u>ARABINOGALACTAN:</u> A plant-based arabinooligosaccharide (AOS), sourced from the alerce tree (*Larix laricina*). It's an excellent prebiotic since it increases the production of short-chain fatty acids, mainly butyrate, which acts as an energy substrate for the epithelial cells of the colon and as protection for the intestinal mucosa. It activates immune response and selectively stimulates the growth and activity of probiotic bacteria ⁽²⁵⁾. It's useful for combating infections because of its capacity to decrease bacterial adherence ⁽²⁶⁻²⁷⁾. Additionally, it reduces the intestinal pH and improves mineral absorption ⁽²⁸⁻³⁰⁾.

Femina Flora Oral





References:

- 1) Reid, Gregor, et al. "Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women." FEMS Immunology & Medical Microbiology 35.2 (2003): 131-134.
- 2) Petricevic, Ljubomir, et al. "Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women." European Journal of Obstetrics & Gynecology and Reproductive Biology 141.1 (2008): 54-57.
- 3) Grewal, Nipunjot, Amita Mahajan, and Jagminder Kaur Bajaj. "The Effect of Supplementation of Standard Antibiotic Therapy with Oral Probiotics for Bacterial Vaginosis." International Journal of Medical and Dental Sciences 7.1 (2018): 1628-1631.
- 4) Reid, Gregor, et al. "Oral probiotics can resolve urogenital infections." FEMS Immunology & Medical Microbiology 30.1 (2001): 49-52.
- 5) Strus, Magdalena, et al. "Studies on the effects of probiotic *Lactobacillus* mixture given orally on vaginal and rectal colonization and on parameters of vaginal health in women with intermediate vaginal flora." European Journal of Obstetrics & Gynecology and Reproductive Biology 163.2 (2012): 210-215.
- 6) Hilton, Eileen, et al. "Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis." Annals of Internal Medicine 116.5 (1992): 353-357.
- 7) Reid, Gregor, et al. "Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora." FEMS Immunology & Medical Microbiology 32.1 (2001): 37-41.
- 8) Anukam, Kingsley, et al. "Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14: randomized, double-blind, placebo controlled trial." Microbes and Infection 8.6 (2006): 1450-1454.
- 9) Grewal, Nipunjot, Amita Mahajan, and Jagminder Kaur Bajaj. "The Effect of Supplementation of Standard Antibiotic Therapy with Oral Probiotics for Bacterial Vaginosis." International Journal of Medical and Dental Sciences 7.1 (2018): 1628-1631.
- 10) Atassi, Fabrice, and Alain L. Servin. "Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain *Lactobacillus johnsonii* NCC933 and vaginal strain *Lactobacillus gasseri* KS120. 1 against enteric, uropathogenic and vaginosis-associated pathogens." FEMS microbiology letters 304.1 (2010): 29-38
- 11) Otero, María Claudia, and María E. Nader-Macías. "Inhibition of Staphylococcus aureus by H2O2-producing Lactobacillus gasseri isolated from the vaginal tract of cattle." Animal reproduction science 96.1-2 (2006): 35-46.
- 12) Phukan, Niha, Anna ES Brooks, and Augusto Simoes-Barbosa. "A cell surface aggregation-promoting factor from Lactobacillus gasseri contributes to inhibition of Trichomonas vaginalis adhesion to human vaginal ectocervical cells." Infection and immunity 86.8 (2018): e00907-17.
- 13) Wang, Shuai, et al. "Antimicrobial compounds produced by vaginal *Lactobacillus crispatus* are able to strongly inhibit *Candida albicans* growth, hyphal formation and regulate virulence-related gene expressions." Frontiers in microbiology 8 (2017): 564.
- 14) Niu, Xiao-Xi, et al. "Lactobacillus crispatus modulates vaginal epithelial cell innate response to Candida albicans." Chinese medical journal 130.3 (2017): 273.
- 15) Fu, Yu-Rong, et al. "Effects of Bifidobacterium bifidum on adaptive immune senescence in aging mice." Microbiology and immunology 54.10 (2010): 578-583.
- 16) De Vrese, Michael, et al. "Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial." Vaccine 24.44 (2006): 6670-6674.
- 17) Park, Ji-Hee, et al. "Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production." Cellular immunology 219.1 (2002): 22-27.
- 18) Makioka, Yuko, et al. "Oral supplementation of *Bifidobacterium longum* strain BR-108 alters cecal microbiota by stimulating gut immune system in mice irrespectively of viability." Bioscience, biotechnology, and biochemistry (2018): 1-8.
- 19) Inturri, Rosanna, et al. "Immunomodulatory Effects of *Bifidobacterium longum* W11 Produced Exopolysaccharide on Cytokine Production." Current pharmaceutical biotechnology 18.11 (2017): 883-889.
- 20) Laparra, José Moisés, et al. "Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model." PLoS One 7.2 (2012): e30744.
- 21) Institute of FoodTechnologists (IFT). What are fructooligosaccharides and how do they provided igestive, immunity and bonehealthbenefits?. Science Daily (2013).
- 22) Gibson, Glenn R. "Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin." The Journal of nutrition 129.7 (1999): 1438S-1441s.
- 23) Flamm, Gary, et al. "Inulin and oligofructose as dietary fiber: a review of the evidence." Critical reviews in food science and nutrition 41.5 (2001): 353-362.
- 24) Cardarelli, Haíssa R., et al. "Inulin and oligofructose improve sensory quality and increase the probiotic viable count in potentially synbiotic petit-suisse cheese." LWT-Food Science and Technology 41.6 (2008): 1037-1046.
- 25) Robinson, Ramona R., Joellen Feirtag, and Joanne L. Slavin. "Effects of dietary arabinogalactan on gastrointestinal and blood parameters in healthy human subjects." Journal of the American College of Nutrition 20.4 (2001): 279-285.
- 26) Gibson, Glenn R. "Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin." The Journal of nutrition 129.7 (1999): 1438S-1441s.
- 27) Flamm, Gary, et al. "Inulin and oligofructose as dietary fiber: a review of the evidence." Critical reviews in food science and nutrition 41.5 (2001): 353-362.
- 28) Van Loo, Jan, et al. "On the presence of inulin and oligofructose as natural ingredients in the western diet." Critical Reviews in Food Science & Nutrition 35.6 (1995): 525-552.
- 29) Niness, Kathy R. "Inulin and oligofructose: what are they?." The Journal of nutrition 129.7 (1999): 1402S-1406s.
- 30) Rao, A. V. "Dose-response effects of inulin and oligofructose on intestinal bifidogenesis effects." The Journal of nutrition 129.7 (1999): 1442S-1445s.